Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hereditary cancers derive from gene defects that often compromise DNA repair. Thus, BRCA-associated cancers are sensitive to DNA-damaging agents such as cisplatin. The efficacy of cisplatin is limited, however, by the development of resistance. One cisplatin resistance mechanism is restoration of homologous recombination (HR), which can result from BRCA reversion mutations. However, in BRCA2 mutant cancers, cisplatin resistance can occur independently of restored HR by a mechanism that remains unknown. Here we performed a genome-wide shRNA screen and found that loss of the nucleosome remodeling factor CHD4 confers cisplatin resistance. Restoration of cisplatin resistance is independent of HR but correlates with restored cell cycle progression, reduced chromosomal aberrations, and enhanced DNA damage tolerance. Suggesting clinical relevance, cisplatin-resistant clones lacking genetic reversion of BRCA2 show de novo loss of CHD4 expression in vitro. Moreover, BRCA2 mutant ovarian cancers with reduced CHD4 expression significantly correlate with shorter progression-free survival and shorter overall survival. Collectively, our findings indicate that CHD4 modulates therapeutic response in BRCA2 mutant cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Biallelic Inactivation of BRCA2 in Fanconi Anemia
Howlett, N. G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., de Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G., et al. (2002) · Science · doi:10.1126/science.1073834 · Cited by 1,149 · cited 1×
“Furthermore, in two other cell lines that contain a truncated BRCA2 mutant (the FA EUFA423 cell line FA-D1 and the pancreatic cancer cell line CAPAN-1) (Howlett et al. 2002; Edwards et al. 2008), CHD4 depletion also increased colony survival following cisplatin treatment (Fig.”
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Translesion synthesis: Y-family polymerases and the polymerase switch
LEHMANN, A., NIIMI, A., OGI, T., BROWN, S., SABBIONEDA, S., WING, J., KANNOUCHE, P., & GREEN, C. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.02.003 · Cited by 389
The NuRD chromatin–remodeling complex regulates signaling and repair of DNA damage
Smeenk, G., Wiegant, W. W., Vrolijk, H., Solari, A. P., Pastink, A., & van Attikum, H. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201001048 · Cited by 243
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190 · cited 2×
“TLS has been shown to mediate cisplatin resistance in cancer models (Wang et al. 2009; Doles et al. 2010; Xie et al. 2010), but aside from monoubiquitination of PCNA, limited biomarkers exist to determine whether TLS is up-regulated.”
Cited by
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
“In another study, loss of the nucleosome remodeling factor CHD4 was found to be associated with cisplatin resistance in BRCA2-mutated tumors (167).”
BackgroundSelf-citationReplication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Self-citationUnderstanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Metadata
- Authors
- Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-03-01
- Volume
- 29
- Issue
- 5
- Pages
- 489-494
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2091230697
- Cited by
- 151
- References
- 8
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. https://app.cochat.ai/papers/10.1101/gad.256214.114
- The paper
- Guillemette, S., Serra, R. W., Peng, M., Hayes, J. A., Konstantinopoulos, P. A., Green, M. R., & Cantor, S. B. (2015). Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes & Development. https://doi.org/10.1101/gad.256214.114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.